Release Date: February 28, 2025
Expiration Date: February 28, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in lung cancer. In this educational program, these experts use a case-based format to discuss the latest advances in lung cancer treatment from curative treatments and novel targeted agents to innovative immunotherapeutic strategies.
This educational activity is an archive of the live symposium held on January 25 and 26, 2025.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in lung cancers and breast cancers. Other health care professionals interested in the treatment of these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Optimize informed clinical decision-making for the management of patients with lung cancers through the use of up-to-date testing strategies and as well as disease specific characteristics
- Integrate emerging clinical trial evidence regarding the management of patients with lung cancers and integrate into personalized treatment selection and sequencing approaches
- Implement appropriate monitoring strategies for adverse events associated with therapies for lung cancer to improve patient outcomes

David R. Gandara, MD
Adjunct Clinical Professor, Translational and Clinical Research Program
University of Hawai‘i Cancer Center
Professor Emeritus
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA
Disclosures: Grant/Research Support: Amgen, Astex Pharmaceuticals, Genentech. Consultant: AstraZeneca, Exact Sciences, Foundation Medicine, Genentech, Guardant Health, Henlius USA. Advisory Board: Janssen, Merck & Co, Mirati Therapeutics, Regeneron Pharmaceuticals.

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Assistant Dean for Translational Research
Deputy Director, Yale Cancer Center
Chief of Hematology/Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Yale School of Medicine
New Haven, CT
Disclosures: Grant/Research Support: Lilly. Consultant: AstraZeneca, Amgen, ArriVent Biopharma, Bristol Myers Squibb, Candel Therapeutics, CatalYm, Checkpoint Therapeutics, Cybrexa Therapeutics, Lilly, Genentech, Gilead Sciences, I-Mab Biopharma, Janssen, Mediflix, Merck & Co, Neuvogen, NextCure, Normunity, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche Holding AG, Sanofi. Shareholder: Checkpoint Therapeutics, Cybrexa Therapeutics, Immunocore, Normunity. Board of Directors: Immunocore, Junshi Pharmaceuticals. Advisory Board: AstraZeneca, Candel Therapeutics. Scientific Advisory Board: Checkpoint Therapeutics, Cybrexa Therapeutics, I-Mab Biopharma, Normunity. Travel: American Association for Cancer Research, AstraZeneca, Friends of Cancer Research, Genentech, International Association for the Study of Lung Cancer, Merck & Co, Southwest Oncology Group.

Heather A. Wakelee, MD, FASCO
Winston Chen and Phyllis Huang Professor
Professor of Medicine
Chief, Division of Oncology
Deputy Director, Stanford Cancer Institute
Stanford University School of Medicine
Past President, International Association for the Study of Lung Cancer
Stanford, CA
Disclosures: Grant/Research Support: AstraZeneca, Bayer, Bristol Myers Squibb Company, Genentech, Helsinn Healthcare, Merck & Co, Seagen, Xcovery. Advisory Board: AstraZeneca (unpaid), BeiGene, Genentech (unpaid), IOBiotech, Merck & Co (unpaid), OncoC4 Other Funds | Lung Cancer CME lecture: Chugai Pharmaceutical (Roche).
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here